Table 1.
Overview of the means ± standard deviations of quality measurements (full width at half maximum, signal-to-noise ratio, Cramér-Rao), pain ratings, and metabolite concentrations in the anterior cingulate cortex
| Rest
|
Acute pain stimulation before treatment
|
Acute pain stimulation during treatment
|
||||
|---|---|---|---|---|---|---|
| Morphine (n=12) | Placebo (n=12) | |||||
| Morphine (n=12) | Placebo (n=12) | Morphine (n=11) | Placebo (n=9) | |||
| FWHM | 0.045±0.012 | 0.042±0.011 | 0.046±0.013 | 0.046±0.010* | 0.046±0.017 | 0.045±0.013 |
| SNR | 14.2±5.7 | 14.8±5.5 | 14.8±3.8 | 14.6±3.0* | 13.6±4.4 | 13.3±4.7 |
| Cramér-Rao (%) | ||||||
| cre | 4.3±2.8 | 4.1±1.6 | 3.7±0.7 | 3.8±1.2 | 3.9±1.0 | 4.2±2.2 |
| glu | 9.2±3.1 | 9.3±2.4 | 8.0±1.3 | 8.8±1.6 | 9.5±1.5 | 9.8±5.1 |
| mI | 6.8±1.9 | 6.7±1.2 | 6.4±0.8 | 6.3±1.1 | 6.7±0.8 | 7.3±5.5 |
| NAA | 4.7±2.7 | 4.6±2.3 | 3.8±0.6 | 4.3±1.4 | 4.5±1.4 | 4.8±2.8 |
| Pain ratings (VAS) | – | – | 6.8±1.0 | 6.5±1.1 | 6.3±1.2 | 6.7±1.1 |
| Metabolite | ||||||
| cre (mM) | 6.80±0.95 | 7.03±0.50 | 6.78±0.75 | 7.04±0.84 | 6.77±0.98 | 6.80±0.57 |
| glu/cre | 1.39±0.29 | 1.32±0.17 | 1.47±0.16 | 1.30±0.16 | 1.31±0.17 | 1.37±0.18 |
| mI/cre | 0.84±0.36 | 0.83±0.21 | 0.84±0.16 | 0.82±0.12 | 0.80±0.15 | 0.79±0.09 |
| NAA/cre | 1.15±0.07 | 1.11±0.12 | 1.24±0.12 | 1.14±0.07 | 1.14±0.06 | 1.19±0.10 |
Notes:
*
Data from one subject are missing; Cramér-Rao, the estimated standard deviation in percent of the estimated concentration.
Abbreviations: FWHM, full width at half maximum; SNR, signal-to-noise ratio; VAS, visual analog scale; cre, creatine; glu, glutamine; mI, myo-inositol; NAA, N-acetylaspartate.